CmaxInsight’s “Chronic Myelocytic Leukemia (CML)-Epidemiology Forecasting Intelligence” report provides a comprehensive analysis of the Chronic Myelocytic Leukemia (CML) epidemiology, providing the historical, current, and forecasted data for the United States, European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom) and Japan during the period from 2018-2028.
Our epidemiology services include:
• Incidence and prevalence
• Diagnosis rate, treatment rate and mortality patterns
• Epidemiology-based forecasting and disease trends
• Size of different patient segments in a disease area
• Population based: disease occurrence, co-morbidities and treatment patterns
• Geographic - Regional - Ethnic differences
Along with the epidemiological data, the report also includes:
• Disease overview, causes, symptoms, classification, risk factor, pathophysiology, diagnosis and treatment
• Patient treatment journey
• Treatment algorithm and guidelines
• Assesses the disease risk and burden
• Highlights the unmet needs
• Market driver and barrier
• Growth opportunities and market trend analysis
Methodology
• This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Epidemiology Forecast model analysis by a team of industry experts.
• To generate accurate patient population estimates, utilizes a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies.
• All of the sources used to generate the data and analysis have been identified in the report.
Note: Systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Interested in this report?
Get your sample now!
1. Report Introduction
2. Chronic Myelocytic Leukemia (CML) Epidemiology Overview at a Glance
3. Market Share Distribution of Chronic Myelocytic Leukemia (CML)
4. Disease Background and Overview: Chronic Myelocytic Leukemia (CML)
4.1. Introduction
4.2. Signs and Symptoms
4.3. Etiology
4.4. Risk Factors
4.5. Pathophysiology
4.6. Diagnostic Landscape
4.6.1. Diagnostic Practices
4.6.2. Diagnostic Criteria
4.6.3. Diagnostic Recommendations
4.7. Treatment Landscape
4.7.1. Current Treatment Practices
4.7.2. Treatment Algorithm
4.7.3. Treatment Recommendations
5. Chronic Myelocytic Leukemia (CML) Epidemiology
5.1. Key Findings
5.2. Assumptions & Rationale
5.3. 7MM Epidemiology
6. Epidemiology of Chronic Myelocytic Leukemia (CML) by Countries
7. United States
7.1. Assumptions and Rationale
7.2. Prevalent/Incident Cases of Chronic Myelocytic Leukemia (CML)
7.3. Sub-Type Specific cases of Chronic Myelocytic Leukemia (CML)*
7.4. Sex- Specific Cases of Chronic Myelocytic Leukemia (CML)*
7.5. Diagnosed Cases of Chronic Myelocytic Leukemia (CML)
7.6. Treated Cases of Chronic Myelocytic Leukemia (CML)
8. EU5
8.1. Germany
8.1.1. Assumptions and Rationale
8.1.2. Prevalent/Incident Cases of Chronic Myelocytic Leukemia (CML)
8.1.3. Sub-Type Specific cases of Chronic Myelocytic Leukemia (CML)*
8.1.4. Sex- Specific Cases of Chronic Myelocytic Leukemia (CML)*
8.1.5. Diagnosed Cases of Chronic Myelocytic Leukemia (CML)
8.1.6. Treated Cases of Chronic Myelocytic Leukemia (CML)
8.2. France
8.2.1. Assumptions and Rationale
8.2.2. Prevalent/Incident Cases of Chronic Myelocytic Leukemia (CML)
8.2.3. Sub-Type Specific cases of Chronic Myelocytic Leukemia (CML)*
8.2.4. Sex- Specific Cases of Chronic Myelocytic Leukemia (CML)*
8.2.5. Diagnosed Cases of Chronic Myelocytic Leukemia (CML)
8.2.6. Treated Cases of Chronic Myelocytic Leukemia (CML)
8.3. United Kingdom
8.3.1. Assumptions and Rationale
8.3.2. Prevalent/Incident Cases of Chronic Myelocytic Leukemia (CML)
8.3.3. Sub-Type Specific cases of Chronic Myelocytic Leukemia (CML)*
8.3.4. Sex- Specific Cases of Chronic Myelocytic Leukemia (CML)*
8.3.5. Diagnosed Cases of Chronic Myelocytic Leukemia (CML)
8.3.6. Treated Cases of Chronic Myelocytic Leukemia (CML)
8.4. Spain
8.4.1. Assumptions and Rationale
8.4.2. Prevalent/Incident Cases of Chronic Myelocytic Leukemia (CML)
8.4.3. Sub-Type Specific cases of Chronic Myelocytic Leukemia (CML)*
8.4.4. Sex- Specific Cases of Chronic Myelocytic Leukemia (CML)*
8.4.5. Diagnosed Cases of Chronic Myelocytic Leukemia (CML)
8.4.6. Treated Cases of Chronic Myelocytic Leukemia (CML)
8.5. Italy
8.5.1. Assumptions and Rationale
8.5.2. Prevalent/Incident Cases of Chronic Myelocytic Leukemia (CML)
8.5.3. Sub-Type Specific cases of Chronic Myelocytic Leukemia (CML)*
8.5.4. Sex- Specific Cases of Chronic Myelocytic Leukemia (CML)*
8.5.5. Diagnosed Cases of Chronic Myelocytic Leukemia (CML)
8.5.6. Treated Cases of Chronic Myelocytic Leukemia (CML)
9. Japan
9.1. Assumptions and Rationale
9.2. Prevalent/Incident Cases of Chronic Myelocytic Leukemia (CML)
9.3. Sub-Type Specific cases of Chronic Myelocytic Leukemia (CML)*
9.4. Sex- Specific Cases of Chronic Myelocytic Leukemia (CML)*
9.5. Diagnosed Cases of Chronic Myelocytic Leukemia (CML)
9.6. Treated Cases of Chronic Myelocytic Leukemia (CML)
10. Unmet Needs
Appendix
Report Methodology
Sources Used
Disclaimer
About CmaxInsight
*Indication Specific
Note: Certain sections of the table of contents would vary according to the availability of information.
Table 1: Total Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in 7MM
Table 2: Total Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in United States
Table 4: Sub-Type Specific Cases of the Chronic Myelocytic Leukemia (CML) in United States*
Table 5: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in United States*
Table 6: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in United States
Table 7: Treated Cases of the Chronic Myelocytic Leukemia (CML) in United States
Table 8: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Germany
Table 9: Sub-Type Specific Cases of the Chronic Myelocytic Leukemia (CML) in Germany*
Table 10: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Germany*
Table 11: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Germany
Table 12: Treated Cases of the Chronic Myelocytic Leukemia (CML) in Germany
Table 13: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in France
Table 14: Sub-Type Specific Cases of the Chronic Myelocytic Leukemia (CML) in France*
Table 15: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in France*
Table 16: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in France
Table 17: Treated Cases of the Chronic Myelocytic Leukemia (CML) in France
Table 18: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Italy
Table 19: Sub-Type Specific Cases of the Chronic Myelocytic Leukemia (CML) in Italy*
Table 20: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Italy*
Table 21: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Italy
Table 22: Treated Cases of the Chronic Myelocytic Leukemia (CML) in Italy
Table 23: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Spain
Table 24: Sub-Type Specific Cases of the Chronic Myelocytic Leukemia (CML) in Spain*
Table 25: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Spain*
Table 26: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Spain
Table 27: Treated Cases of the Chronic Myelocytic Leukemia (CML) in Spain
Table 28: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in UK
Table 29: Sub-Type Specific Cases of the Chronic Myelocytic Leukemia (CML) in UK*
Table 30: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in UK*
Table 31: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in UK
Table 32: Treated Cases of the Chronic Myelocytic Leukemia (CML) in UK
Table 33: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Japan
Table 34: Sub-Type Specific Cases of the Chronic Myelocytic Leukemia (CML) in Japan*
Table 35: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Japan*
Table 36: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Japan
Table 37: Treated Cases of the Chronic Myelocytic Leukemia (CML) in Japan
*Indication Specific
Figure 1: Total Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in United States
Figure 4: Sub-Type Specific Cases of the Chronic Myelocytic Leukemia (CML) in United States*
Figure 5: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in United States*
Figure 6: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in United States
Figure 7: Treated Cases of the Chronic Myelocytic Leukemia (CML) in United States
Figure 8: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Germany
Figure 9: Sub-Type Specific Cases of the Chronic Myelocytic Leukemia (CML) in Germany*
Figure 10: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Germany*
Figure 11: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Germany
Figure 12: Treated Cases of the Chronic Myelocytic Leukemia (CML) in Germany
Figure 13: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in France
Figure 14: Sub-Type Specific Cases of the Chronic Myelocytic Leukemia (CML) in France*
Figure 15: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in France*
Figure 16: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in France
Figure 17: Treated Cases of the Chronic Myelocytic Leukemia (CML) in United France
Figure 18: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Italy
Figure 19: Sub-Type Specific Cases of the Chronic Myelocytic Leukemia (CML) in Italy*
Figure 20: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Italy*
Figure 21: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Italy
Figure 22: Treated Cases of the Chronic Myelocytic Leukemia (CML) in Italy
Figure 23: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Spain
Figure 24: Sub-Type Specific Cases of the Chronic Myelocytic Leukemia (CML) in Spain*
Figure 25: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Spain*
Figure 26: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Spain
Figure 27: Treated Cases of the Chronic Myelocytic Leukemia (CML) in Spain
Figure 28: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in UK
Figure 29: Sub-Type Specific Cases of the Chronic Myelocytic Leukemia (CML) in UK*
Figure 30: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in UK*
Figure 31: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in UK
Figure 32: Treated Cases of the Chronic Myelocytic Leukemia (CML) in UK
Figure 33: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Japan
Figure 34: Sub-Type Specific Cases of the Chronic Myelocytic Leukemia (CML) in Japan*
Figure 35: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Japan*
Figure 36: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Japan
Figure 37: Treated Cases of the Chronic Myelocytic Leukemia (CML) in Japan
*Indication Specific
